vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Up 33.1% in January

vTv Therapeutics Inc. (NASDAQ:VTVT) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 22,500 shares, an increase of 33.1% from the December 31st total of 16,900 shares. Approximately 1.5% of the company’s shares are sold short. Based on an average daily volume of 29,400 shares, the short-interest ratio is presently 0.8 days.

Analyst Ratings Changes

Separately, Alliance Global Partners assumed coverage on shares of vTv Therapeutics in a report on Monday, December 9th. They issued a “buy” rating and a $35.00 price target on the stock.

vTv Therapeutics Price Performance

Shares of vTv Therapeutics stock opened at $14.66 on Friday. The business has a fifty day simple moving average of $14.73 and a two-hundred day simple moving average of $15.19. vTv Therapeutics has a 12 month low of $8.03 and a 12 month high of $30.99.

vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.88) EPS for the quarter.

Institutional Trading of vTv Therapeutics

A hedge fund recently bought a new stake in vTv Therapeutics stock. FMR LLC acquired a new stake in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 178,200 shares of the biotechnology company’s stock, valued at approximately $2,402,000. FMR LLC owned 5.92% of vTv Therapeutics as of its most recent SEC filing. Institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.